pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

WADA international standard Prohibited list and feature4,5,36)

Substances and methods prohibited at all times Feature Medication used for the treatment
S0 Non-approved substances
S1 Anabolic agents • Anabolic effect
• Enhancement of performance
• Male hypogonadism
S2 Peptide hormones, growth factors, related substances, and mimetics
1. Erythropoietins (EPO) and agents affecting erythropoiesis
2. Peptide hormones and their releasing factors
3. Growth factors and growth factor modulators
• Anabolic effect
• Oxygen transfer enhancement
• Improve performance
• Anaemia
• Male hypogonadism
• Growth hormone deficiency
S3 Beta-2 agonists • Anabolic effect
• stimulant
• Asthma
• Other respiratory disorders
S4 Hormone and metabolic modulators
1. Aromatase inhibitors
2. Anti-estrogenic substances anti-estrogens and selective estrogen receptor modulator (SERMS)
3. Agents preventing activin receptor IIB activation
4. Metabolic modulators
• Enhancement of performance • Breast cancer
• Diabetes
• Infertility (female)
• Polycystic ovarian syndrome
S5 Diuretics and masking agents • Lose weight quickly
• Difficult detection in urine as it enhances the speed of elimination of performance enhance drugs
• Heart failure
• Hypertension
Prohibited methods at all times Feature
M1 Manipulation of blood and blood components Increase the oxygen delivery and the aerobic capacity
M2 Chemical and physical manipulation • Intravenous infusions or injections except for hospital treatments, surgical procedures and clinical diagnostic investigations
M3 Gene and cell doping • Change of gene expression
• Enhancement of performance
Substances prohibited in-competition Feature Medication used for the treatment
S6 Stimulants • Direct and peripheral effect on the nervous system
• Enhancement of performance
• Anaphylaxis
• Attention deficit hyperactivity disorders (ADHD)
• Cold and influenza symptoms
S7 Narcotics • pain control to interact with opioid receptor • Pain including from musculoskeletal injuries
S8 Cannabinoids • Ergogenic effect
S9 Glucocorticoids • Ergogenic effect
• Anti-inflammatory effect
• Allergy
• Anaphylaxis
• Asthma
• Inflammatory bowel disease
Substances prohibited in particular sports Feature Medication used for the treatment
P1 Beta-blockers • Improve performance • Heart failure
• Hypertension
Korean J Clin Pharm 2021;31:12-20 https://doi.org/10.24304/kjcp.2021.31.1.12
© 2021 Korean J Clin Pharm